ReviewImmunotherapy2010
Personalized dendritic cell-based tumor immunotherapy.
Review in Immunotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Review
- Cancer Immunotherapy Using Bioengineered Micro/Nano Structured Hydrogels.Advanced healthcare materials · 2023Review
- Potential Application of Exosomes in Vaccine Development and Delivery.Pharmaceutical research · 2022Review
- Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.World journal of gastroenterology · 2021Review
- Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Frontiers in immunology · 2021Review
- Network- and systems-based re-engineering of dendritic cells with non-coding RNAs for cancer immunotherapy.Theranostics · 2021Article
- Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8International journal of nanomedicine · 2020Article
- Mesenchymal Stem Cells Beyond Regenerative Medicine.Frontiers in cell and developmental biology · 2020Review
- Dendritic cells loaded with CD44Oncology letters · 2019Article
- Engineering anti-cancer nanovaccine based on antigen cross-presentation.Bioscience reports · 2019Review
- In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.Scientific reports · 2016Article
- The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Targeted immunotherapy for pediatric solid tumors.Oncoimmunology · 2016Review
- Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection.Immune network · 2014Article
- Monitoring the efficacy of dendritic cell vaccination by early detection of (99m) Tc-HMPAO-labelled CD4(+) T cells.European journal of immunology · 2014Article
- Investigations of the functional states of dendritic cells under different conditioned microenvironments by Fourier transformed infrared spectroscopy.Biomedical engineering online · 2014Article
- Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Critical reviews in immunology · 2014Review
- Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their limitations and the future challenges for effective immunotherapy against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.